Limaca Medical Ltd. has developed the Precision-GI™ Endoscopic Biopsy Device, which aims to enhance the accuracy and efficiency of endoscopic biopsies, particularly for diagnosing gastrointestinal cancers. This innovative device features a motorized, automated, rotating cutting mechanism that allows for superior tissue acquisition with minimal blood contamination, enabling physicians to obtain high-quality samples in a single pass. The Precision-GI™ device has received FDA clearance as of August 2023 and is designed to standardize outcomes across varying levels of physician skill, thereby reducing the dependency on manual techniques that often result in non-diagnostic rates and inconsistent sample quality.

The company is dedicated to improving the standard of care in endoscopic procedures, particularly for pancreatic, liver, and lung cancers. By addressing the limitations of traditional manual biopsy tools, Limaca Medical's Precision-GI™ device offers a more efficient and reliable method for obtaining tissue samples suitable for histological and molecular analysis. The device's automated features not only streamline the biopsy process but also enhance the potential for personalized cancer treatment by ensuring that high-quality tissue samples are consistently available for genetic profiling and diagnosis.

Israel

Limaca Medical Ltd, is a privately held company dedicated to improving endoscopic biopsy results for patients facing potentially life-threatening gastroenterology and pulmonary cancers. 
Limaca's experienced team of engineers, clinicians, and business professionals have track records of innovating, developing, and commercializing specialized medical devices.
Limaca Medical was founded in 2017 in cooperation with Rambam Health Care, a leading Israeli medical center, and The Trendlines Group in collaboration with the Israel Innovation Authority.

Limaca Medical Ltd

Company Details